Metabolic-Syndrome-Related Comorbidities in Narcolepsy Spectrum Disorders: A Preliminary Cross-Sectional Study in Japan

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2022 May 28

PMID 35627822

Authors

Kunihiro Futenma

Yoshikazu Takaesu

Masaki Nakamura

Kenichi Hayashida

Noboru Takeuchi

Yuichi Inoue

Affiliations

Soon will be listed here.

Abstract

Narcolepsy types 1 (NT1) and 2 (NT2) and idiopathic hypersomnia (IH) are thought to be a disease continuum known as narcolepsy spectrum disorders (NSDs). This study aimed to assess the prevalence of and factors associated with metabolic-syndrome-related disorders (MRDs) among patients with NSD. Japanese patients with NSD (NT1, = 94; NT2, = 83; and IH, = 57) aged ≥35 years were enrolled in this cross-sectional study. MRD was defined as having at least one of the following conditions: hypertension, diabetes, or dyslipidemia. Demographic variables and MRD incidence were compared among patients in the respective NSD categories. Multivariate logistic regression analysis was used to investigate the factors associated with MRDs. Patients with NT1 had a higher body mass index (BMI) and incidence of MRD than that had by those with NT2 or IH. Age, BMI, and the presence of OSA were significantly associated with the incidence of MRD in NSDs. Age and BMI in NT1, BMI and human leukocyte antigen (HLA)-DQB1*06:02 positivity in NT2, and only age in IH were factors associated with the incidence of MRD. Obesity should be carefully monitored in narcolepsy; however, NT2 with HLA-DQB1*06:02 positive should be followed up for the development of MRD even without obesity.

Citing Articles

Investigation of the relationship between sleep-related parameters and metabolic syndrome (MetS) among youths in the Southeast of Iran.

Kazemi M, Khalili P, Kazemi M, Hasani H, Sadeghi M, Jamali Z Diabetol Metab Syndr. 2023; 15(1):91.

PMID: 37147707 PMC: 10161496. DOI: 10.1186/s13098-023-01072-3.

Body Weight and Metabolic Rate Changes in Narcolepsy: Current Knowledge and Future Directions.

Dhafar H, BaHammam A Metabolites. 2022; 12(11).

PMID: 36422261 PMC: 9693066. DOI: 10.3390/metabo12111120.

References

Postiglione E, Barateau L, Pizza F, Lopez R, Antelmi E, Rassu A . Narcolepsy with intermediate cerebrospinal level of hypocretin-1. Sleep. 2021; 45(2). DOI: 10.1093/sleep/zsab285. View

Sasai T, Inoue Y, Komada Y, Sugiura T, Matsushima E . Comparison of clinical characteristics among narcolepsy with and without cataplexy and idiopathic hypersomnia without long sleep time, focusing on HLA-DRB1( *)1501/DQB1( *)0602 finding. Sleep Med. 2009; 10(9):961-6. DOI: 10.1016/j.sleep.2008.12.007. View

Dauvilliers Y, Baumann C, Carlander B, Bischof M, Blatter T, Lecendreux M . CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry. 2003; 74(12):1667-73. PMC: 1757412. DOI: 10.1136/jnnp.74.12.1667. View

Ponziani V, Gennari M, Pizza F, Balsamo A, Bernardi F, Plazzi G . Growing Up with Type 1 Narcolepsy: Its Anthropometric and Endocrine Features. J Clin Sleep Med. 2016; 12(12):1649-1657. PMC: 5155189. DOI: 10.5664/jcsm.6352. View

Mignot E, Hayduk R, Black J, Grumet F, Guilleminault C . HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 1998; 20(11):1012-20. View

Nishino S, Ripley B, Overeem S, Lammers G, Mignot E . Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000; 355(9197):39-40. DOI: 10.1016/S0140-6736(99)05582-8. View

Nakamura M, Kanbayashi T, Sugiura T, Inoue Y . Relationship between clinical characteristics of narcolepsy and CSF orexin-A levels. J Sleep Res. 2010; 20(1 Pt 1):45-9. DOI: 10.1111/j.1365-2869.2010.00870.x. View

Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S . Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb. 2018; 25(9):846-984. PMC: 6143773. DOI: 10.5551/jat.GL2017. View

Dauvilliers Y, Jaussent I, Krams B, Scholz S, Lado S, Levy P . Non-dipping blood pressure profile in narcolepsy with cataplexy. PLoS One. 2012; 7(6):e38977. PMC: 3387234. DOI: 10.1371/journal.pone.0038977. View

10.

Kribbs N, Pack A, Kline L, Smith P, Schwartz A, Schubert N . Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis. 1993; 147(4):887-95. DOI: 10.1164/ajrccm/147.4.887. View

11.

Andlauer O, Moore 4th H, Hong S, Dauvilliers Y, Kanbayashi T, Nishino S . Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep. 2012; 35(9):1247-55F. PMC: 3413802. DOI: 10.5665/sleep.2080. View

12.

Drager L, Togeiro S, Polotsky V, Lorenzi-Filho G . Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol. 2013; 62(7):569-76. PMC: 4461232. DOI: 10.1016/j.jacc.2013.05.045. View

13.

Reading P . Cataplexy. Pract Neurol. 2018; 19(1):21-27. DOI: 10.1136/practneurol-2018-002001. View

14.

Bastianini S, Silvani A, Berteotti C, Elghozi J, Franzini C, Lenzi P . Sleep related changes in blood pressure in hypocretin-deficient narcoleptic mice. Sleep. 2011; 34(2):213-8. PMC: 3022942. DOI: 10.1093/sleep/34.2.213. View

15.

Yokoyama H, Hiroshi H, Ohgo H, Hibi T, Saito I . Effects of excessive ethanol consumption on the diagnosis of the metabolic syndrome using its clinical diagnostic criteria. Intern Med. 2007; 46(17):1345-52. DOI: 10.2169/internalmedicine.46.6196. View

16.

Nakanishi N, Takatorige T, Suzuki K . Cigarette smoking and the risk of the metabolic syndrome in middle-aged Japanese male office workers. Ind Health. 2005; 43(2):295-301. DOI: 10.2486/indhealth.43.295. View

17.

Ohayon M, Black J, Lai C, Eller M, Guinta D, Bhattacharyya A . Increased mortality in narcolepsy. Sleep. 2014; 37(3):439-44. PMC: 3920308. DOI: 10.5665/sleep.3470. View

18.

Sonka K, Susta M, Billiard M . Narcolepsy with and without cataplexy, idiopathic hypersomnia with and without long sleep time: a cluster analysis. Sleep Med. 2015; 16(2):225-31. DOI: 10.1016/j.sleep.2014.09.016. View

19.

Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014; 37(4):253-390. DOI: 10.1038/hr.2014.20. View

20.

Mignot E, Lammers G, Ripley B, Okun M, Nevsimalova S, Overeem S . The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002; 59(10):1553-62. DOI: 10.1001/archneur.59.10.1553. View